- Home
- TYGO vs CNTB Comparison
TYGO vs CNTB Comparison
Compare TYGO & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- CNTB
- Stock Information
- Founded
- TYGO 2007
- CNTB 2012
- Country
- TYGO United States
- CNTB United States
- Employees
- TYGO N/A
- CNTB N/A
- Industry
- TYGO Semiconductors
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- CNTB Health Care
- Exchange
- TYGO Nasdaq
- CNTB Nasdaq
- Market Cap
- TYGO 58.9M
- CNTB 53.9M
- IPO Year
- TYGO N/A
- CNTB 2021
- Fundamental
- Price
- TYGO $0.97
- CNTB $1.05
- Analyst Decision
- TYGO Buy
- CNTB Strong Buy
- Analyst Count
- TYGO 3
- CNTB 1
- Target Price
- TYGO $3.00
- CNTB $8.00
- AVG Volume (30 Days)
- TYGO 321.1K
- CNTB 28.0K
- Earning Date
- TYGO 02-11-2025
- CNTB 09-05-2024
- Dividend Yield
- TYGO N/A
- CNTB N/A
- EPS Growth
- TYGO N/A
- CNTB N/A
- EPS
- TYGO N/A
- CNTB N/A
- Revenue
- TYGO $45,985,000.00
- CNTB $24,116,000.00
- Revenue This Year
- TYGO N/A
- CNTB N/A
- Revenue Next Year
- TYGO $57.24
- CNTB $63.90
- P/E Ratio
- TYGO N/A
- CNTB N/A
- Revenue Growth
- TYGO N/A
- CNTB N/A
- 52 Week Low
- TYGO $0.76
- CNTB $0.90
- 52 Week High
- TYGO $2.12
- CNTB $2.66
- Technical
- Relative Strength Index (RSI)
- TYGO 53.32
- CNTB 45.74
- Support Level
- TYGO $0.76
- CNTB $1.01
- Resistance Level
- TYGO $0.89
- CNTB $1.40
- Average True Range (ATR)
- TYGO 0.17
- CNTB 0.13
- MACD
- TYGO -0.00
- CNTB -0.01
- Stochastic Oscillator
- TYGO 24.37
- CNTB 25.53
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.